Patents by Inventor Tim Beaumont

Tim Beaumont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gram-positive bacteria specific binding compounds
    Patent number: 9927428
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 27, 2018
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • RSV G PROTEIN SPECIFIC ANTIBODIES
    Publication number: 20170342134
    Abstract: The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Application
    Filed: June 30, 2017
    Publication date: November 30, 2017
    Inventors: Tim Beaumont, Etsuko Yasuda
  • Means and methods for influencing the stability of antibody producing cells
    Patent number: 9822339
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: November 21, 2017
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
  • INFLUENZA A VIRUS SPECIFIC ANTIBODIES
    Publication number: 20170313766
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 2, 2017
    Inventors: Hergen SPITS, Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Arjen Quirinus BAKKER
  • HEPATITIS C VIRUS SPECIFIC ANTIBODY
    Publication number: 20170313764
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for hepatitis C virus (HCV). The invention further relates to the use of such antibodies for diagnosis, treatment and prevention of HCV infection.
    Type: Application
    Filed: September 7, 2015
    Publication date: November 2, 2017
    Inventors: Tim BEAUMONT, Sabrina Julia Louisa MERAT, Cornelia Johanna SCHINKEL, Richard MOLENKAMP
  • MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS
    Publication number: 20170306293
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Application
    Filed: June 2, 2017
    Publication date: October 26, 2017
    Inventors: HERGEN SPITS, FERENC A. SCHEEREN, TIM BEAUMONT, SEAN A. DIEHL
  • Influenza A virus specific antibodies
    Patent number: 9718874
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: August 1, 2017
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • RSV G protein specific antibodies
    Patent number: 9718876
    Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: August 1, 2017
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • Gram-positive bacteria specific binding compounds
    Patent number: 9688745
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: June 27, 2017
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20170067880
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 9, 2017
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • EX VIVO ANTIBODY PRODUCTION
    Publication number: 20170009205
    Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
    Type: Application
    Filed: December 24, 2014
    Publication date: January 12, 2017
    Inventors: Pauline Maria Wilhelmina VAN HELDEN, Mark Jeroen KWAKKENBOS, Hergen SPITS, Tim BEAUMONT
  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20160326261
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 10, 2016
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah Hazenberg
  • Gram-positive bacteria specific binding compounds
    Patent number: 9458228
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 4, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20160251412
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 1, 2016
    Applicant: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20160244509
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: February 18, 2016
    Publication date: August 25, 2016
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20160222096
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: December 28, 2015
    Publication date: August 4, 2016
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L.W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Gram-positive bacteria specific binding compounds
    Patent number: 9399673
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 26, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES
    Publication number: 20160194382
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Application
    Filed: February 19, 2016
    Publication date: July 7, 2016
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Hergen SPITS, Adrianus Quirinus BAKKER
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20160168232
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: March 5, 2013
    Publication date: June 16, 2016
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • RSV-specific binding molecules and means for producing them
    Patent number: 9321831
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 26, 2016
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda